Worldwide Clinical Trials Brings Decades of Knowledge to Your Mild Cognitive Impairment Study
Mild cognitive impairment (MCI) is a neurological condition that often precedes but is distinct from Alzheimer’s disease and other dementia-related diseases. The condition varies in each individual, so the challenge for researchers is to establish a clear set of identifying markers. Because there is currently no pharmacological treatment for MCI, there is vast opportunity for researchers to make advances. And with a growing population of aging individuals, the need for more understanding of MCI and possible treatment therapies is becoming more pronounced.
From our inception as a contract research organization, Worldwide Clinical Trials has been advancing knowledge in the field of dementia-related conditions. With an array of full-service Alzheimer’s disease and dementia trials under our belt, including studies of mild cognitive impairment, Worldwide’s team of medical, scientific, and research experts is the force you need to bring your MCI study to its best possible outcome.